

Haematologica  
HAEMATOL/2019/216903  
Version 3

Impact of hypertensive emergency and complement rare variants on presentation and outcome of atypical hemolytic uremic syndrome

Khalil El Karoui, Idris Boudhabhay, Florent Petitprez, Paula Vieira-Martins, Fadi Fakhouri, Julien Zuber, Florence Aulagnon, Marie Matignon, Eric Rondeau, Laurent Mesnard, Jean-Michel Halimi, and Véronique Frémeaux-Bacchi

Disclosures: KEK have received travel support from Alexion Pharmaceuticals. VFB have received consultancy and/or lecture fees and/or travel support from Alexion Pharmaceuticals, Roche, Apellis. JMH have received consultancy and/or lecture fees and/or travel support from Alexion Pharmaceuticals and Ablynx. VFB serves as coordinator of the scientific advisory board of Alexion M11-001 atypical hemolytic uremic syndrome international registry.

Contributions: VFB and KEK designed the study. VFB and PVM performed the genetic screening and the Complement assessment. IB, FA and KEK collected clinical data. VFB, KEK and JMH analyzed the data, and wrote the manuscript. All authors contributed to patients' recruitment and clinical data collection, discussed the results and contributed to the final manuscript.